Abstract
This paper discusses the effects of BRCA1 in sporadic breast cancer. It analyzes studies that suggest that non-genetic risk factors may differ in women who have a BRCA1 or BRCA2 mutation more than in women who do not have such a mutation. It describes each of the three studies and their conclusions, but suggests that further studies need to be done to examine the exact effects and possible prevention of the BRCA1 mutation.

From the Paper
"Surprisingly, closely similar findings were described in each of the three studies, though scientists doing the studies expected to find these results. In the Netherlands study, they described for the first time the high expression of EGFR in breast cancers related to BRCA1 or BRCA2 mutations (van der Groep, et al. 615). In the Korean study, BRCA-associated tumors showed lower ER, PR, and HER-2/neu and higher p53 expression, findings in accordance with previous studies, though the ages of the subjects were found to be younger than those of other studies. Also, in the Korean study, BRCA1 and BRCA2 mutations did not identify any of the founder mutations common to western populations, though they admit that more population-based studies need to be done. They found that the BRCA1 anomaly had characteristics indicating either higher mitotic activity or no tubule formation, often with lymphocytic infiltration. In all cases, BRCA2 mutations were invasively cancerous. There were other factors that each study admitted had influences on analysis, such as sporadic carcinogenetic pathways, age, family history and estrogen and progesterone receptors. The Netherlands study added that the expression of Ki57 and EGFR was found to be related to sporadic cancer. The Icelandic study found phenotypic similarities between BRCA1 methylated and familial BRCA1 breast tumors (Birgisdotter, et al. 9)."

Tags:BRCA2, lymphocyte, tumor

Abstract
This paper discusses the effects of BRCA1 in sporadic breast cancer. It analyzes studies that suggest that non-genetic risk factors may differ in women who have a BRCA1 or BRCA2 mutation more than in women who do not have such a mutation. It describes each of the three studies and their conclusions, but suggests that further studies need to be done to examine the exact effects and possible prevention of the BRCA1 mutation.

From the Paper
"Surprisingly, closely similar findings were described in each of the three studies, though scientists doing the studies expected to find these results. In the Netherlands study, they described for the first time the high expression of EGFR in breast cancers related to BRCA1 or BRCA2 mutations (van der Groep, et al. 615). In the Korean study, BRCA-associated tumors showed lower ER, PR, and HER-2/neu and higher p53 expression, findings in accordance with previous studies, though the ages of the subjects were found to be younger than those of other studies. Also, in the Korean study, BRCA1 and BRCA2 mutations did not identify any of the founder mutations common to western populations, though they admit that more population-based studies need to be done. They found that the BRCA1 anomaly had characteristics indicating either higher mitotic activity or no tubule formation, often with lymphocytic infiltration. In all cases, BRCA2 mutations were invasively cancerous. There were other factors that each study admitted had influences on analysis, such as sporadic carcinogenetic pathways, age, family history and estrogen and progesterone receptors. The Netherlands study added that the expression of Ki57 and EGFR was found to be related to sporadic cancer. The Icelandic study found phenotypic similarities between BRCA1 methylated and familial BRCA1 breast tumors (Birgisdotter, et al. 9)."

Tags:BRCA2, lymphocyte, tumor